New drug trial aims to tame severe asthma attacks
NCT ID NCT06653322
Summary
This study is testing an investigational drug called SHR-1703 to see if it can reduce the number of serious asthma flare-ups in people with a specific type of asthma driven by high eosinophil blood cells. About 400 participants with poorly controlled asthma despite current medications will receive either the drug or a placebo for 48 weeks. The main goal is to see if the drug lowers the yearly rate of asthma attacks requiring extra treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA WITH EOSINOPHILIC PHENOTYPE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China School of Medicine West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, 610041, China
Contact
Conditions
Explore the condition pages connected to this study.